(IN BRIEF) Almirall and Absci have expanded their AI-based drug discovery collaboration by selecting a second dermatological target, following the initial success of AI-designed antibody leads against a difficult-to-drug protein. Their partnership, active since November 2023, leverages Absci’s Integrated Drug … Read the full press release →
Posted in Artificial Intelligence (AI), Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Spain, Technology
Tagged Absci, AI drug discovery, Almirall, antibody leads, biotech collaboration, chronic skin disease, clinical development, de-novo design, Dermatology, generative AI, Integrated Drug Creation, Karl Ziegelbauer, milestone payments, partnership, Sean McClain, second target, wet-lab validation